BioSpace News Archive

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX),today announced it had signed a non-binding letter of intent (“LOI”) to acquire a company focused on developing Point-of-Care diagnostics for early detection of diseases including cancers and SARS-CoV-2 (COVID-19) through a range of non-invasive and affordable point of care and at-home/in-office test kits.

Fate Therapeutics, Inc. (NASDAQ: FATE), today presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology Annual Meeting and Exposition.

Senti Bio, a leading gene circuit company, announced new preclinical data from its gene circuit-engineered allogeneic CAR-NK cell therapy pipeline in a session yesterday at the American Society of Hematology (ASH) Annual Meeting and Exposition being held December 11–14.

While one in four blood cancer patients do not produce detectable antibodies after their first two doses of the COVID-19 vaccine, 43% of them will produce antibodies after a third dose, according to new data from The Leukemia & Lymphoma Society (LLS).

Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today it has completed its acquisition of Hillrom.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), announced today new and updated results from the CARTITUDE clinical development program studying ciltacabtagene autoleucel (cilta-cel) in the treatment of multiple myeloma, which were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

Rheos Medicines, today announced new preclinical data supporting MALT1 inhibition as a novel approach for the treatment of chronic Graft-Versus-Host Disease (cGVHD) and the use of differential metabolic pathway analysis to subset patients in this heterogeneous population.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced new updates on its vaccine and therapeutic development programs focused on COVID-19.

GlycoMimetics, Inc. (Nasdaq: GLYC) this week at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta presented two posters providing support for targeting both CXCR4 and E-selectin with GMI-1359, the Company’s dual antagonist of CXCR4 and E-selectin, as a novel treatment strategy for patients with AML.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the presentation of two posters related to its lead liquid tumor candidates TSC-100 and TSC-101.